Life sciences executive to join Patheon
Gilles Cottier to lead the company’s PDS business.
Patheon has appointed Gilles Cottier as president of the company’s pharmaceutical development services (PDS) division effective immediately. He will serve as a member of Patheon’s executive committee and will report to Patheon CEO James Mullen.
The appointment of Cottier is part of a larger realignment effort by the company to create three distinct business segments – drug product services (DPS), drug substance services (DSS) and PDS. This will help the company forge deeper relationships with clients and employ new business models to help clients simplify their supply chain management activities. Patheon’s three business segments are led by key executives: Franco Negron for DPS, Lukas Utiger for DSS and now Cottier for PDS.
Cottier will assume the responsibilities for the PDS business from Michael Lehmann who was leading both Global PDS and Global Sales and Marketing. Lehmann will now focus on the Sales and Marketing function to support the expanding number of new business opportunities and increasing complexity of client relationships.
“Gilles brings a wealth of relevant experience in the life science and technology sector, including the manufacture of chemical and biochemical compounds, contract manufacturing and commercial services,” said Mullen. “I’d also like to thank Mike Lehmann for his outstanding leadership of the PDS business during his tenure. We established ourselves as the global market leader of PDS services.”
Cottier joins Patheon from Sigma-Aldrich Corporation where he was executive vice president and president of the Sigma-Aldrich Fine Chemicals (SAFC) Commercial Unit overseeing the contract manufacturing and the commercial services business unit which achieved more than $700 million in sales in 2014.
Cottier held numerous positions of increasing responsibility at Sigma-Aldrich during his more than 25 years with the company. He earned a master’s degree in organic chemistry from the Ecole Supérieure de Chimie Industrielle de Lyon, France and advanced management program from the Harvard Business School in Boston, MA.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance